FIELD: medicine.
SUBSTANCE: invention aims at individual prediction of the therapeutic efficacy of chronic hepatitis C with pegylated interferon-alpha and ribavirin. The stages of the hepatic fibrosis from F0 to F4, the thrombocyte count, genotypes of the polymorphous rs12979860 locus of IL28B gene, anti-VHC IgM level, the presence of anti-NS5a IgG and the relation of anti-NS4ab IgG to anti-NS3 IgG titres are valued; thereafter the derived values are scored. The total score is derived, and if the total score of a prediction criterion is within the range of +9 to +6, a high probability of achieving a sustained virological response (SVR) is stated. The value falling within the range of +5 to +2, a good probability of achieving the SVR is stated, however a recurrence is considered to be possible. If the value exceeds +1, a moderate possibility of the SVR is considered with a very possible recurrence. The value from 0 to -9 is not to be associated with achieving the SVR.
EFFECT: method enables effective selecting patients for a standard dual antiviral therapy of chronic hepatitis C with underlying new therapeutic regimens.
3 tbl, 10 ex
